A better buy-in window may exist right now for NewAmsterdam Pharma Company NV (NAMS)

With 1.37 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.98 million shares. The 52-week range on NAMS shows that it touched its highest point at $27.29 and its lowest point at $15.19 during that stretch. It currently has a 1-year price target of $44.33. Beta for the stock currently stands at -0.08.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NAMS was up-trending over the past week, with a rise of 13.33%, but this was up by 13.06% over a month. Three-month performance surged to 19.12% while six-month performance rose 48.56%. The stock gained 6.87% in the past year, while it has lost -7.39% so far this year. A look at the trailing 12-month EPS for NAMS yields -2.60 with Next year EPS estimates of -1.80. For the next quarter, that number is -0.50. This implies an EPS growth rate of 29.13% for this year and -0.28% for next year.

Float and Shares Shorts:

At present, 108.06 million NAMS shares are outstanding with a float of 56.66 million shares on hand for trading.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. EBITDA for the full year was $33.80M.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NAMS since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.96973 being high and -$2.32689 being low. For NAMS, this leads to a yearly average estimate of -$2.22948. Based on analyst estimates, the high estimate for the next quarter is -$0.37 and the low estimate is -$0.5. The average estimate for the next quarter is thus -$0.43.